Physician profile
Irfan Ahsan
NPI 1871904862
$21,115.49
in general payments reported to CMS, 2019-2025
14 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $370 · 2023: $986 · 2024: $745 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $9,000 · Travel and Lodging: $5,801 · Food and Beverage: $4,517 · Education: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $9,000.00 |
| Travel and Lodging | $5,801.07 |
| Food and Beverage | $4,517.37 |
| Education | $1,427.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12,630.37 | 2022-2025 | Tacticath, Assurity, Ensite |
| Boston Scientific Corporation | $4,887.31 | 2025 | General - Therapies, Emblem Mri S-Icd |
| Biosense Webster, INC. | $2,002.06 | 2025 | Carto 3 |
| Medtronic, INC. | $679.26 | 2025 | Micra |
| Atricure, INC. | $412.62 | 2023-2024 | |
| Biotronik INC. | $189.74 | 2024 | Biomonitor |
| Ancora Heart, INC. | $134.47 | 2022 | |
| Angiodynamics, INC. | $64.49 | 2025 | Alphavac, Angiovac |
| Philips North America LLC | $27.28 | 2025 | Bridge |
| Organogenesis INC. | $21.50 | 2024 | |
| Pfizer INC. | $17.02 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $16.68 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $16.44 | 2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.25 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Ahsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.